Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Niagen Bioscience (NAGE) Total Current Liabilities: 2011-2025

Historic Total Current Liabilities for Niagen Bioscience (NAGE) over the last 12 years, with Sep 2025 value amounting to $22.7 million.

  • Niagen Bioscience's Total Current Liabilities rose 28.32% to $22.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $22.7 million, marking a year-over-year increase of 28.32%. This contributed to the annual value of $17.9 million for FY2024, which is 12.97% down from last year.
  • As of Q3 2025, Niagen Bioscience's Total Current Liabilities stood at $22.7 million, which was up 1.72% from $22.3 million recorded in Q2 2025.
  • In the past 5 years, Niagen Bioscience's Total Current Liabilities registered a high of $22.7 million during Q3 2025, and its lowest value of $16.2 million during Q2 2021.
  • For the 3-year period, Niagen Bioscience's Total Current Liabilities averaged around $19.7 million, with its median value being $19.4 million (2023).
  • In the last 5 years, Niagen Bioscience's Total Current Liabilities declined by 12.97% in 2024 and then increased by 28.32% in 2025.
  • Niagen Bioscience's Total Current Liabilities (Quarterly) stood at $17.6 million in 2021, then climbed by 1.45% to $17.9 million in 2022, then rose by 15.41% to $20.6 million in 2023, then decreased by 12.97% to $17.9 million in 2024, then rose by 28.32% to $22.7 million in 2025.
  • Its Total Current Liabilities stands at $22.7 million for Q3 2025, versus $22.3 million for Q2 2025 and $20.8 million for Q1 2025.